Reduces elevated serum total and LDL-C. ANDA 217667, held by Edenbridge Pharms. Colestipol Hydrochloride.
As of Nov 16, 2026, ANDA 217667 (Colestipol Hydrochloride), held by Edenbridge Pharms, was first approved by FDA on Aug 16, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 16, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colestipol Hydrochloride1GM · tablet;oral | Colestipol Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters